CapsoVision CV
NASDAQ CV
$6.37 +0.01 (+0.16%)
At close: Sep 9, 2026 · 4:00 PM EDT

CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025)

CapsoVision's (CV) quarterly Preferred Stock Liabilities came in at $143.6 million in Q2 2025, up 11.66% year-over-year from $128.6 million in Q2 2024, and little changed quarter-over-quarter from $143.6 million in Q4 2024.

Analysis

CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends

CapsoVision has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $143.6 million for Q2 2025.

  • In Q2 2025, Preferred Stock Liabilities rose 11.66% year-over-year to $143.6 million; the TTM figure through Jun 2025 stood at $143.6 million (up 11.66% YoY), while the FY2024 annual figure was $143.6 million, changed N/A from the prior year.
  • Preferred Stock Liabilities came in at $143.6 million for Q2 2025 at CapsoVision, roughly flat from $143.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $143.6 million in Q4 2024 to a low of $128.6 million in Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 GE HealthCare Technologies 31.10 Bn 29.22 Bn 2.18 Bn -
2 Lantheus Holdings 6.59 Bn 6.00 Bn 241.86 Mn -
3 Heartflow 4.24 Bn 3.87 Bn 53.19 Mn -
4 Neogen 2.58 Bn 2.39 Bn 107.80 Mn -
5 Butterfly Network 1.75 Bn 1.62 Bn 23.29 Mn -
6 QuidelOrtho 954.15 Mn 830.75 Mn - -
7 Ceribell 944.88 Mn 815.62 Mn 25.94 Mn -
8 Anbio Biotechnology 941.05 Mn 929.15 Mn - -
9 Varex Imaging 780.16 Mn 694.86 Mn 76.70 Mn -
10 CapsoVision 299.69 Mn 290.62 Mn 1.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 143.63 Mn
Dec 31, 2024 143.63 Mn
Sep 30, 2024 138.63 Mn
Jun 30, 2024 128.63 Mn